Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Adalimumab

Brand: Humira®
NICE TA: 329
Indication: Second line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LMMG Recommendation
Disease category: Gastro-intestinal system
Commissioning responsibility: CCG
PbR excluded: Yes

Background

In UC patients who experience intolerance, secondary failure or primary failure with a first line biologic in line with NICE TA329 or TA342, adalimumab should be used in preference to alternative TNF-alpha inhibitors where it is available.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red